The authors conclude that KRAS mutation status can be used to identify the subgroup of patients with irinotecan-refractory metastatic CRC who are most likely to respond to cetuximab.
According to the National Cancer Institute's website, KRAS is a gene that makes a protein involved in cell signaling pathways that regulate cell growth, maturation and death. The normal form of the ...
In a recent trial, researchers found that Xpovio plus chemo had activity in NSCLC patients with KRAS mutations other than ...
Initial validation using orthotopic models: SIL204 administered subcutaneously (systemically) showed significant efficacy in ...
Verastem's assets, Avutometinib and Defactinib, show promising results in treating KRAS-mutated LGSOC. Read why VSTM stock is a Hold.
Silexion's SIL204 reduced tumor growth and metastases in pancreatic cancer models, showing strong efficacy across KRAS ...
FDA-approved drugs sotorasib and adagrasib have given new hope to some patients by targeting this KRAS G12C mutation ... FGTI-2734 blocks cancer cells' wild type RAS membrane localization ...
5don MSN
A breakthrough in lung cancer treatment may be on the horizon. Scientists at VCU Massey Comprehensive Cancer Center have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback